Novo Nordisk A/S investors sue for securities fraud between May 7 and July 28, 2025.

Levi & Korsinsky has filed a class action lawsuit against Novo Nordisk A/S (NVO) on behalf of investors who were allegedly misled by the company's positive statements and concealment of material facts about its growth potential between May 7, 2025 and July 28, 2025. Investors who suffered losses may contact Joseph E. Levi, Esq. via email or phone to learn more and be contacted by a member of the team.

New York, July 02, 2025 — Levi & Korsinsky, LLP has filed a class action lawsuit against Novo Nordisk A/S (NVO) on behalf of investors who were allegedly misled by the company's positive statements and concealment of material facts about its growth potential between May 7, 2025 and July 28, 2025. Investors who suffered losses are encouraged to contact Joseph E. Levi, Esq. via email or phone to learn more and be contacted by a member of the team.

The lawsuit alleges that Novo Nordisk made materially false and misleading statements and/or failed to disclose that its representations regarding growth potential were overstated and did not account for the impact of the personalization exception to the compounded GLP-1 exclusion. Additionally, the complaint asserts that Novo Nordisk misrepresented the likelihood that patients using compounded GLP-1s would transition to the company's branded alternatives and overstated the size of the GLP-1 market and its ability to penetrate that market to sustain growth [3].

On July 29, 2025, Novo Nordisk announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The company attributed the guide down to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expectations, and competition." Following this news, the price of Novo's common stock declined dramatically from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day [3].

Investors who suffered losses during the relevant time frame have until September 30, 2025, to request that the Court appoint them as lead plaintiff. However, appointment as lead plaintiff is not required to partake in any recovery. There is no cost or obligation to participate in the case [3].

Levi & Korsinsky, LLP has a track record of representing investors in complex securities litigation and has secured hundreds of millions of dollars for aggrieved shareholders. For seven years in a row, the firm has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States [3].

References:

[1] https://www.morningstar.com/news/globe-newswire/9510553/nvo-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-novo-nordisk-as-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit
[2] https://www.morningstar.com/news/globe-newswire/9513090/robbins-llp-urges-nvo-stockholders-with-large-losses-to-contact-the-firm-for-information-about-leading-the-class-action-against-novo-nordisk-as
[3] https://www.morningstar.com/news/globe-newswire/9512158/investors-in-novo-nordisk-as-should-contact-levi-korsinsky-before-september-30-2025-to-discuss-your-rights-nvo
[4] https://www.prnewswire.com/news-releases/nvo-lawsuit-alert-the-gross-law-firm-notifies-novo-nordisk-as-investors-of-a-class-action-lawsuit-and-upcoming-deadline-302529610.html